Affiliation: EORTC Data Center
- Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council L Collette
European Organization for Research and Treatment of Cancer, Data Center, Brussels, Belgium
J Natl Cancer Inst 91:839-46. 1999....
- Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differencesL Collette
European Organization for Research and Treatment of Cancer, EORTC Data Center, Brussels, Belgium
Prostate 48:29-39. 2001..The meta-analysis of maximal androgen blockade (MAB) concluded that there is no survival advantage of MAB over castration alone. However, the results from the largest trials yield conflicting results...
- Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary GroupLaurence Collette
European Organisation for Research and Treatment of Cancer, Data Center Biostatistics, Ave E Mounier 83 11, B 1200 Brussels, Belgium
J Clin Oncol 22:3877-85. 2004....
- Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)Laurence Collette
EORTC Data Center, Rue E Mounier 83, B 11, B 1200 Brussels, Belgium
Eur Urol 44:182-9; discussion 189. 2003..We study the value of PSA response and PSA progression as prognostic factors for survival in good prognosis metastatic prostate cancer...
- Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)Oscar Matzinger
European Organisation for Research and Treatment of Cancer EORTC, Headquarters, Brussels, Belgium
Acta Oncol 49:24-34. 2010..We present the toxicity reported until year 3 after treatment...
- Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trialsLaurence Collette
European Organisation for Research and Treatment of Cancer EORTC Data Center, Avenue E Mounier 83 11, 1200 Brusells, Biostatistics Department, Brussels, Belgium
Eur J Cancer 42:1344-50. 2006..We give some recommendations for the planning of trials that would use PSA endpoints (in hormone refractory disease) and for the early stop of (endocrine treatment) trials on the basis of intermediate results based on PSA...
- Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and Laurence Collette
European Organization for Research and Treatment of Cancer Data Center, Avenue Emmanuel Mounier 83 11, B 1200 Brussels, Belgium
J Clin Oncol 23:6139-48. 2005..It could be shortened by using surrogate end points. Prostate-specific antigen (PSA) is the most studied biomarker in prostate cancer (PCa). This study attempts to validate PSA end points as surrogates for OS in advanced PCa...
- Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st centuryTom Budiharto
EORTC Head Quarters, Brussels, Belgium
Radiother Oncol 88:403-10. 2008..The first step is the evaluation of the structure and of the human, technical and organisational resources of the centres, to assess their ability to comply with the current requirements for high-tech radiotherapy (RT)...
- Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863Fatma Ataman
EORTC Data Center, Radiotherapy Group, Avenue E Mounier 83, Bte 11, B 1200 Brussels, Belgium
Eur J Cancer 40:1674-81. 2004..Although four treatment-related deaths (1%) occurred, grade 3 or 4 late complications were less than 5%...
- Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodesElena Musat
EORTC, Avenue E Mounierlaan, 83 11, 1200 Brussels, Belgium
Eur J Cancer 43:718-24. 2007..In the final trial analysis, a sensitivity analysis should evaluate the subgroup of patients receiving an optimal treatment to verify the robustness of the results and the true impact of IM-MS irradiation...
- Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?Frederic E Lecouvet
Department of Radiology, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
Eur Urol 62:68-75. 2012..However, this two-step approach has limited sensitivity and specificity...
- EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomachOscar Matzinger
EORTC Headquarters, Brussels, Belgium
Radiother Oncol 92:164-75. 2009..The Gastro-Intestinal Working Party of the EORTC Radiation Oncology Group (GIWP-ROG) developed guidelines for target volume definition in neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction (GEJ) and the stomach...
- Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)Laurence Collette
European Organisation for Research and Treatment of Cancer EORTC Data Center Biostatistics, Avenue E Mounier 83 11, B 1200, Brussels, Belgium
Eur J Cancer 41:2662-72. 2005..Postoperative irradiation improved biochemical progression-free survival in all patient groups. Longer follow-up is needed to assess the endpoint of clinical progression-free survival...
- Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer RadLaurence Collette
Statistics Department, European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
J Clin Oncol 25:4379-86. 2007..We further explored the data with the aim of refining our understanding of the long-term results...
- Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'Sandra Collette
Statistics Department, EORTC Headquarters, Brussels, Belgium
Eur J Cancer 44:2587-99. 2008..01) if WBI was given with >6 MV photons. The c-index was around 0.62. Nomograms with these factors are proposed to forecast the long-term risk of moderate or severe fibrosis...
- Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II studyJean Luc Van Laethem
Department of Gastroenterology, Erasme University Hospital, Universite Libre de Bruxelles, Brussels, Belgium
J Clin Oncol 28:4450-6. 2010..This randomized phase II intergroup study explores the feasibility and tolerability of a gemcitabine-based CRT regimen after R0 resection of pancreatic head cancer...
- What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?Cora N Sternberg
San Camillo and Forlanini Hospitals, Rome, Italy, and EORTC Data Center, Biostatistics Department, Brussels, Belgium
BJU Int 98:487-9. 2006
- Prophylactic cranial irradiation in extensive small-cell lung cancerBen Slotman
Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
N Engl J Med 357:664-72. 2007..We conducted a randomized trial of prophylactic cranial irradiation in patients with extensive small-cell lung cancer who had had a response to chemotherapy...
- Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trialHarry Bartelink
Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
J Clin Oncol 25:3259-65. 2007..To investigate the long-term impact of a boost radiation dose of 16 Gy on local control, fibrosis, and overall survival for patients with stage I and II breast cancer who underwent breast-conserving therapy...
- Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trialsLaurence Collette
Eur Urol 53:6-9. 2008
- Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911Theodorus H van der Kwast
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and University Health Network, Toronto, Canada
J Clin Oncol 25:4178-86. 2007..Review pathology data of specimens from participants in this trial were analyzed to identify which factors predict increased benefit from adjuvant radiotherapy...
- Quality of surgery in T3-4 rectal cancer: involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC trial 22921Marcel den Dulk
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
Eur J Cancer 43:1821-8. 2007....
- Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trialMichel Bolla
University Hospital, Grenoble, France
Lancet 360:103-6. 2002..INTERPRETATION: Immediate androgen suppression with an LHRH analogue given during and for 3 years after external irradiation improves disease-free and overall survival of patients with locally advanced prostate cancer...
- Adjuvant radiotherapy after surgery for pathologically advanced prostate cancerTheodorus H van der Kwast
J Clin Oncol 25:5671-2. 2007
- Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!Laurence Collette
J Clin Oncol 25:5673-4; author reply 5674. 2007
- Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)Urs E Studer
Department of Urology, University Hospital of Bern, Switzerland
Eur Urol 53:941-9. 2008..The question arises whether serum prostate-specific antigen (PSA) levels may be used to decide when to initiate ADT in PCa not suitable for local curative treatment...
- Chemotherapy with preoperative radiotherapy in rectal cancerJean Francois Bosset
Department of Radiation Therapy, University of Franche Comte, Besancon, France
N Engl J Med 355:1114-23. 2006..Preoperative radiotherapy is recommended for selected patients with rectal cancer. We evaluated the addition of chemotherapy to preoperative radiotherapy and the use of postoperative chemotherapy in the treatment of rectal cancer...
- Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladderPhilip M Poortmans
Department of Radiation Oncology, Dr Bernard Verbeeten Institute, Tilburg, The Netherlands
Acta Oncol 47:937-40. 2008..We prospectively evaluated concomitant radiotherapy and chemotherapy for advanced bladder cancer in a phase II EORTC trial to test whether it could be further studied as a potential treatment of bladder cancer...
- Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostateAnthony V D'Amico
Department of Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Cancer 109:2004-10. 2007....
- EORTC prostate cancer trials: what have we learnt?Theo M de Reijke
Department of Urology, Academic Medical Center, Meibergdreef 9, Amsterdam, The Netherlands
Crit Rev Oncol Hematol 43:159-65. 2002....
- Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual periodPhilip M P Poortmans
Department of Radiotherapy, Dr Bernard Verbeeten Instituut, Tilburg, The Netherlands
Radiother Oncol 76:278-84. 2005..To evaluate the impact of quality assurance on treatment compliance, we compared the outcome of the two individual case reviews (ICR) conducted early and late during the accrual period of a large prospective multi-centre trial...
- Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921Jean Francois Bosset
Centre Hospitalier Universitaire Besançon, France
J Clin Oncol 23:5620-7. 2005..We investigated the effect of adding CT on the pathologic parameters...
- Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)Michel Bolla
Department of Radiation Oncology, Centre Hospitalier Universitaire A Michallon, Grenoble, France
Lancet 366:572-8. 2005..We did a randomised controlled trial to compare radical prostatectomy followed by immediate external irradiation with prostatectomy alone for patients with positive surgical margin or pT3 prostate cancer...
- Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892Fritz H Schroder
Department of Urology, Erasmus MC, P O Box 2040 3000 CA Rotterdam, The Netherlands
Eur Urol 45:457-64. 2004..The results pertaining to sexual function were already reported [Br J Cancer 82(2) (2000) 283]...
- Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility studyWalter Albrecht
Department of Urology, Rudolfstiftung, Juchgasse 25, A 1030, Vienna, Austria
Eur Urol 44:505-11. 2003..In preparation of an intercontinental Phase III trial comparing continuous maximal androgen blockade (MAB) to intermittent androgen suppression (IAS) in untreated metastatic prostate cancer, a feasibility study on IAS was accomplished...
- Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911)Theodorus H van der Kwast
Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada, and Department of Urology, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
Virchows Arch 449:428-34. 2006..05 and p>0.8). The observations suggest that review of pathological stage and surgical margin of radical prostatectomy strongly improves their prognostic impact in multi-institutional studies or trials...
- Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomyUrs E Studer
Eur Urol 50:887-9; discussion 889-92. 2006
- Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882Ninja Antonini
Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Radiother Oncol 82:265-71. 2007..To determine whether the effect of an additional "boost" radiation after breast conservative therapy (BCT) on local control depends on age and evaluate the impact of a treatment policy with a threshold for age...
- Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III studyFritz H Schroder
Department of Urology, Erasmus Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
J Urol 172:923-7. 2004..The issue is addressed in protocol 30846 of the European Organisation for Research and Treatment of Cancer for patients with lymph node positive cancer without local treatment of the primary tumor...
- Quality assurance in the EORTC randomized trial 22922/10925 investigating the role of irradiation of the internal mammary and medial supraclavicular lymph node chain worksPhilip Poortmans
Department of Radiotherapy, Dr Bernard Verbeeten Instituut, Tilburg, The Netherlands
Strahlenther Onkol 182:576-82. 2006..The results of a dummy run procedure and of an individual case review are compared to each other. The effects of recommendations based on QA procedures on the protocol compliance are evaluated...
- Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20)Sophie D Fossa
Norwegian Radium Hospital, Oslo, Norway
J Clin Oncol 21:1107-18. 2003..To describe global quality of life (GLQL) in patients with metastatic testicular cancer (TC) treated with four different schedules of bleomycin, etoposide, and cisplatin (BEP) chemotherapy (four v three cycles given over 5 v 3 days)...
- Palliative-care trials: how best to publish findings?Murielle E Mauer
Lancet Oncol 9:411-2. 2008
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialBernard Nordlinger
centre hospitalier universitaire Ambroise Paré, Assistance Publique Hopitaux de Paris, Departments of Surgery and Oncology, Boulogne Billancourt, France
Lancet 371:1007-16. 2008..We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer...
- Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891Urs E Studer
Department of Urology, University Hospital of Bern, Bern, Switzerland
J Clin Oncol 24:1868-76. 2006..This study (EORTC 30891) attempted to demonstrate equivalent overall survival in patients with localized prostate cancer not suitable for local curative treatment treated with immediate or deferred androgen ablation...
- Clinical trial designs for predictive marker validation in cancer treatment trialsDaniel J Sargent
Mayo Clinic, Kahler 1A, 200 First St, SW, Rochester, MN 55905, USA
J Clin Oncol 23:2020-7. 2005..We discuss the advantages and disadvantages of the two trial designs and their appropriateness to specific clinical situations to assist investigators seeking to design rigorous, marker-based clinical trials...
- Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studiesMaurizio Brausi
Institute Sant'Agostino, Estense, Modena, Italy
Eur Urol 41:523-31. 2002..It is suggested that the quality of the TUR performed by the individual surgeons may be responsible...
- The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trialPhilip Poortmans
Department of Radiotherapy, Dr. Bernard Verbeeten Institute, Tilburg, The Netherlands
Radiother Oncol 72:25-33. 2004....
- Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancerMassimo Maffezzini
Department of Urology, Ospedali Galliera, Genoa, Italy
Eur Urol 51:605-13; discussion 613. 2007..To review the methodology of PSA doubling time (PSA DT) calculations and the implications of PSA DT for the follow-up of prostate cancer patients curatively treated with surgery or radiation therapy...